在肺癌治疗中利用进化免疫学来进行介质素-6和介质素-17信号传递
Riya Khilwani1, Shailza Singh1
1Systems Medicine Laboratory, BRIC-National Centre for Cell Science, NCCS Complex, Ganeshkhind, SPPU Campus, Pune 411007, India.
ACS pharmacology & translational science
|December 19, 2024
概括
互乐金-6 (IL-6) 和互乐金-17 (IL-17) 细胞因子通过抑制免疫反应,矛盾地促进肺癌. 准这些细胞因子中的保存残留物可能为对抗肺癌提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 进化生物学 进化生物学
背景情况:
- 肺癌是癌症死亡的主要原因,与治疗耐药性相关的发病率上升.
- 免疫调节和化疗耐药性有助于增加肺癌病例.
- 介乐-6 (IL-6) 和介乐-17 (IL-17) 是关键的细胞因子,参与恶性肺细胞内的免疫反应.
研究的目的:
- 研究IL-6和IL-17在肺癌发育和进展中的作用.
- 探索IL-6和IL-17的进化关系和结构特征.
- 为了确定这些细胞因子中的潜在治疗点,用于肺癌治疗.
主要方法:
- 对肺癌中细胞因子信号通路的分析.
- 细胞因子基因演变的进化建模和统计分析.
- 在IL-6和IL-17中识别保存的结构残留物.
主要成果:
- 过度的IL-6和IL-17促进免疫抑制瘤微环境,增强癌细胞存活率和转移.
- 这些细胞因子有助于抗亡机制和瘤发生.
- 进化分析揭示了IL-6和IL-17之间的保存结构和祖先关系.
结论:
- IL-6和IL-17在肺癌中起着双重作用,促进瘤生长和免疫逃避.
- 在IL-6和IL-17内保存的残留物代表了治疗干预的潜在目标.
- 开发针对这些保护区的疫苗或抑制剂可能为肺癌治疗提供新的途径.
更多相关视频
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.3K
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
7.6K
相关概念视频
Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
T Cell Types and Functions
947
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
947
